Gilead Sciences agreed to acquire Arcellx for $7.8 billion to take full control of anito‑cel, a BCMA‑directed CAR‑T candidate nearing regulatory review. The purchase price includes $115 per share in cash plus a contingent value right tied to future sales. The BLA for anito‑cel is under FDA review with a PDUFA date in December 2026. By internalizing the program, Gilead removes profit‑sharing and milestone obligations and positions its cell‑therapy unit to compete directly with Johnson & Johnson/Legend Biotech’s Carvykti, which generated nearly $1.9 billion in 2025 sales.